IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.
200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 1mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Antibody Type:
Recombinant Monoclonal Antibody
Application Notes:
Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes),Optimal dilutio
* VAT and and shipping costs not included. Errors and price changes excepted
